4D Molecular Therapeutics (FDMT) Receives a Buy from SVB Securities

SVB Securities analyst Mani Foroohar maintained a Buy rating on 4D Molecular Therapeutics (FDMTResearch Report) today and set a price target of $28.00. The company’s shares closed last Thursday at $9.42, close to its 52-week low of $9.06.

According to TipRanks.com, Foroohar is ranked 0 out of 5 stars with an average return of -26.1% and a 31.3% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Recursion Pharmaceuticals, and Rocket Pharmaceuticals.

4D Molecular Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $34.00.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $36.14 and a one-year low of $9.06. Currently, 4D Molecular Therapeutics has an average volume of 198.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

4D Molecular Therapeutics Inc is a development stage precision gene therapy company. It engages in developing a broad pipeline of transformative gene therapy product candidates designed to treat patients suffering from lysosomal storage diseases, lung diseases, muscular dystrophies, and ophthalmic diseases. The AAV vectors are designed to provide targeted delivery by routine clinical routes, efficient transduction, reduced immunogenicity and resistance to pre-existing antibodies which enable to develop gene therapies.

Read More on FDMT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More